Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Calidi Biotherapeutics (CLDI)
NYSE MKT:CLDI
RESEARCH TOOLSreports
Calidi Biotherapeutics (CLDI) Stock Price & Analysis
50 Followers
CLDI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.14 - $13.79
Previous Close$0.2
Volume1.40M
Average Volume (3M)1.04M
Market Cap
$9.64M
Enterprise Value$14.12M
Total Cash (Recent Filing)$1.95M
Total Debt (Recent Filing)$6.43M
Price to Earnings (P/E)-0.2
Beta0.33
Next Earnings
Mar 15, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding35,538,034
10 Day Avg. Volume2,647,546
30 Day Avg. Volume1,040,207
Standard Deviation0.20
R-Squared0.02
Alpha-0.10
Financial Highlights & Ratios
Price to Book (P/B)-0.85
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$3.25Price Target Upside1447.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Calidi Biotherapeutics News
PremiumCompany Announcements
Calidi Biotherapeutics Shares Informative Investor Presentation SlidesPremiumCompany Announcements
Calidi Biotherapeutics Bolsters Finance with Strategic Offering
PremiumCompany Announcements
Calidi Biotherapeutics Issues Regulation FD Disclosure Notice
PremiumCompany Announcements
Calidi Biotherapeutics Restructures Debt and Streamlines FinancesBulls Say, Bears Say
Bulls Say
Clinical MilestonesEncouraging early clinical data showing prolonged survival times for glioma patients treated with CLD-101 may signal a breakthrough in the treatment of high-grade gliomas.
Financial SupportThe $5.3M grant awarded to Calidi's collaborator, City of Hope, is a strong vote of confidence and a financial boost that could accelerate the development of its promising cancer therapies.
Innovation And DevelopmentCalidi Biotherapeutics' cutting-edge RTNova program offers a new hope in treating advanced solid tumors, potentially revolutionizing care for lung and metastatic cancer patients.
Bears Say
Financial PerformanceFinancial results reported a net loss wider than previously forecast.
Financial StabilityShares are likely to remain pressured until the company is able to add to its cash runway, with a recent trend of approximately $5M cash burn from operations per quarter.
Liquidity ConcernsCLDI currently has a relatively short cash runway, which appears to be already pressuring the stock.
---
Ownership Overview
7.73% Insiders
1.31% Mutual Funds
0.65% Other Institutional Investors
90.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLDI FAQ
What was Calidi Biotherapeutics’s price range in the past 12 months?
Calidi Biotherapeutics lowest stock price was $0.14 and its highest was $13.79 in the past 12 months.
What is Calidi Biotherapeutics’s market cap?
Currently, no data Available
When is Calidi Biotherapeutics’s upcoming earnings report date?
Calidi Biotherapeutics’s upcoming earnings report date is Mar 15, 2024 which is 54 days ago.
How were Calidi Biotherapeutics’s earnings last quarter?
Calidi Biotherapeutics released its earnings results on Nov 14, 2023. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.03.
Is Calidi Biotherapeutics overvalued?
According to Wall Street analysts Calidi Biotherapeutics’s price is currently Undervalued.
Does Calidi Biotherapeutics pay dividends?
Calidi Biotherapeutics does not currently pay dividends.
What is Calidi Biotherapeutics’s EPS estimate?
Calidi Biotherapeutics’s EPS estimate is -$0.21.
How many shares outstanding does Calidi Biotherapeutics have?
Calidi Biotherapeutics has 48,959,286 shares outstanding.
What happened to Calidi Biotherapeutics’s price movement after its last earnings report?
Calidi Biotherapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Calidi Biotherapeutics?
Among the largest hedge funds holding Calidi Biotherapeutics’s share is Driehaus Capital Management LLC. It holds Calidi Biotherapeutics’s shares valued at 143K.
---
Calidi Biotherapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.25 (1447.62% Upside)
$3.25 (1447.62% Upside)
Hedge Fund Trend
Decreased
By 125.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.08%
12-Months-Change
Fundamentals
Return on Equity
-115.44%
Trailing 12-Months
Asset Growth
-76.62%
Trailing 12-Months
Company Description
Calidi Biotherapeutics
First Light Acquisition Group Inc is a is a blank check company. It is formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
---
CLDI Stock 12 Months Forecast
Average Price Target
$3.25
▲(1447.62% Upside)
Technical Analysis
Best Analysts Covering CLDI
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-77.90%
reiterated a buy rating 2 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -77.90% per trade.
---